Advertisement

Topics

AstraZeneca to divest remaining anaesthetics portfolio rights

06:48 EDT 14 Sep 2017 | PharmaTimes

Rights will be sold to Aspen in $766 million deal

Original Article: AstraZeneca to divest remaining anaesthetics portfolio rights

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca to divest remaining anaesthetics portfolio rights"

Quick Search
Advertisement